Back to Journals » Drug Design, Development and Therapy » Therapeutic advances in adipose tissue dysfunction and bone health in obesity and insulin resistance
Drug Design, Development and Therapy
ISSN: 1177-8881
- View all (4136)
- Volume 18, 2024 (97)
- Volume 17, 2023 (283)
- Volume 16, 2022 (316)
- Volume 15, 2021 (399)
- Volume 14, 2020 (477)
- Volume 13, 2019 (387)
- Volume 12, 2018 (382)
- Volume 11, 2017 (330)
- Volume 10, 2016 (374)
- Volume 9, 2015 (543)
- Volume 8, 2014 (231)
- Volume 7, 2013 (143)
- Volume 6, 2012 (42)
- Volume 5, 2011 (40)
- Volume 4, 2010 (35)
- Volume 3, 2009 (27)
- Volume 2, 2008 (29)
- Volume 1, 2007 (1)
Journal Articles:
- Beyond Brain Boundaries: Overcoming the Blood-Brain Barrier to Reach the Central Nervous System (1)
- Using Innovative Drug Delivery Systems to Improve the Efficacy and Applicability of Poorly Water-soluble Drugs (1)
- Advances in design and development of ophthalmic drugs (5)
- A cross-sectional survey on heart failure from China: disease burden and management (3)
- Ten Years of Biosimilars in Europe (4)
Therapeutic advances in adipose tissue dysfunction and bone health in obesity and insulin resistance
The adipose tissue is a large and varied endocrine organ, consisting of different types of fat cells and other cell types (i.e., endothelial cells, fibroblasts, and immune cells) with unique secretory properties. It can influence almost every aspect of body function. In mammals, the adipose tissue grows and develops in utero in relation to maternal blood glucose levels, and if challenged after birth with overnutrition, it may continue to expand almost indefinitely, causing obesity and its attendant metabolic consequences, such as insulin resistance. This Article Collection focuses on the latest pharmacological advances for treating obesity, insulin resistance, and their related metabolic/health consequences.